Keyword price-impact finder

How stocks move after “Phase 3” headlines

Late-stage clinical trial news. Every single-ticker headline on the Quantisnow wire containing “Phase 3” in the last 12 months, measured to the next close.

After 653 headlines containing “Phase 3” (627 distinct stock-sessions), the stock moved -0.69% on average by the next close (median -0.06%), and closed higher 48% of the time.

Average move
-0.69%
Next close vs prior close
Median move
-0.06%
Closed higher
48%
Share of stock-sessions
Avg absolute move
8.72%
Volatility around the headline
Sample
627
Stock-sessions from 653 headlines
Average vs SPY
-0.78%
Move minus SPY same session
5-session average
-0.37%
Median -0.39%, 613 headlines

How often it shows up

Per day
1.79
Per month
54.5
Per year
653
020406080Nov 25: Headlines 23Nov 25Dec 25: Headlines 56Jan 26: Headlines 32Jan 26Feb 26: Headlines 35Mar 26: Headlines 69Mar 26Apr 26: Headlines 42May 26: Headlines 58May 26Jun 26: Headlines 74Jul 26: Headlines 43Jul 26Aug 26: Headlines 50Sep 26: Headlines 63Sep 26Oct 26: Headlines 78Nov 26: Headlines 30Nov 26
Single-ticker headlines containing “Phase 3” per month. The latest month is to date.

Distribution of next-close moves

Recent headlines

Date (UTC)TickerHeadlineNext close5 sessions
2026-11-11 14:45LLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity+0.35%-
2026-11-11 13:00AMGNAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE+0.62%-
2026-11-11 13:00NTHINeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100+3.43%-
2026-11-10 13:01LPCNLipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression-7.56%-
2026-11-10 13:01JNJJohnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study-0.47%-
2026-11-10 12:30MIRMMirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD+1.33%-
2026-11-09 21:01BDTXBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC-14.25%-
2026-11-09 14:00CAPRCapricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology+9.44%-
2026-11-09 13:30VTGNVistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder+12.58%-
2026-11-09 12:00MANEVeradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss+3.73%-
2026-11-09 12:00COAGHemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia-12.67%-
2026-11-09 11:30ABEOAbeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement-39.09%-
2026-11-08 23:00MANEVeradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss+3.73%-
2026-11-08 21:15VIRVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta+11.75%-
2026-11-06 21:00BMYBristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions+0.00%-
2026-11-05 15:00VIRVir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call-6.37%+11.55%
2026-11-05 15:00GILDPositive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)-3.96%-2.72%
2026-11-05 13:00OSTXOS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial-14.77%-24.16%
2026-11-05 13:00EWTXEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring+3.57%+26.75%
2026-11-05 13:00ARQTArcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis-20.70%-16.65%
2026-11-05 12:30BHVNBiohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting-8.79%-0.33%
2026-11-05 12:30AGENAgenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study-7.60%+3.59%
2026-11-04 13:00NTLAIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)+3.79%-5.82%
2026-11-04 12:00DFTXDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress-2.13%+3.68%
2026-11-04 12:00RADXRadiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases-2.37%-5.29%

Methodology